TAMPA, Fla., July 27 /PRNewswire/ — Moffitt Cancer
Center and CvergenX, Inc., announced today
that they have entered into a licensing agreement under which
CvergenX has acquired the exclusive worldwide rights to a
technology platform that individualizes radiation therapy,
InterveneXRT™. Researchers at Moffitt have used gene
expression analysis and systems biology to create a
radio-sensitivity classification index for individual tumors.
“While genomic analysis has been applied in the development of
diagnostic tools to guide chemotherapy use, this is the first time
that the field has expanded to radiation therapy,” said
Dr. Javier F. Torres-Roca, the radiation oncologist who
co-founded CvergenX with
Steven A. Eschrich, Ph.D., both Moffitt faculty members.
“Radiation therapy has undergone vast changes with
significant improvements in